Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Turner Kathy V

2. Date of Event Requiring Statement (MM/DD/YYYY) 5/9/2018

3. Issuer Name and Ticker or Trading Symbol

IDEXX LABORATORIES INC /DE [IDXX]

(Last) (First) (Middle)

C/O IDEXX LABORATORIES, INC., ONE IDEXX DRIVE

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
Corporate Vice President /

(Street)

WESTBROOK, ME 04092

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2806	D
Common Stock	100 ⁽¹⁾	I	by spouse

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Stock Unit	⁽²⁾	⁽²⁾	Common Stock	3870 ⁽²⁾	⁽²⁾	D
Non-Qualified Stock Option (right-to-buy)	⁽³⁾	5/31/2024	Common Stock	276 ⁽¹³⁾	$64.24 ⁽¹³⁾	D
Incentive Stock Option (right-to-buy)	⁽⁴⁾	5/31/2024	Common Stock	7780 ⁽¹³⁾	$64.24 ⁽¹³⁾	D
Non-Qualified Stock Option (right-to-buy)	⁽⁵⁾	2/13/2025	Common Stock	19354 ⁽¹³⁾	$79.54 ⁽¹³⁾	D
Incentive Stock Option (right-to-buy)	⁽⁶⁾	2/13/2025	Common Stock	1256 ⁽¹³⁾	$79.54 ⁽¹³⁾	D
Non-Qualified Stock Option (right-to-buy)	⁽⁷⁾	2/13/2026	Common Stock	22028	$67.85	D
Incentive Stock Option (right-to-buy)	⁽⁸⁾	2/13/2026	Common Stock	1476	$67.85	D
Non-Qualified Stock Option (right-to-buy)	⁽⁹⁾	2/13/2027	Common Stock	10386	$141.60	D
Incentive Stock Option (right-to-buy)	⁽¹⁰⁾	2/13/2027	Common Stock	706	$141.60	D
Non-Qualified Stock Option (right-to-buy)	⁽¹¹⁾	2/13/2028	Common Stock	10148	$178.26	D
Incentive Stock Option (right-to-buy)	⁽¹²⁾	2/13/2028	Common Stock	560	$178.26	D

Explanation of Responses:
(1)	The reporting person disclaims beneficial ownership of the shares of common stock held by her spouse except to the extent of her pecuniary interest therein.
(2)	Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the "Stock Split").
(3)	Grant of option to buy 138 shares of Issuer common stock that vests in five annual installments beginning on June 1, 2015, without giving effect to the Stock Split.
(4)	Grant of option to buy 3,890 shares of Issuer common stock that vests in one installment on June 1, 2019, without giving effect to the Stock Split.
(5)	Grant of option to buy 4,993 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2016, without giving effect to the Stock Split.
(6)	Grant of option to buy 628 shares of Issuer common stock that vests in one installment on February 14, 2020, without giving effect to the Stock Split.
(7)	Grant of option to buy 11,347 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2017.
(8)	Grant of option to buy 1,474 shares of Issuer common stock that vests as to 1 share on February 14, 2017, February 14, 2018 and February 14, 2020, respectively, and as to the remainder on February 14, 2021.
(9)	Grant of option to buy 10,386 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2018.
(10)	Grant of option to buy 706 shares of Issuer common stock that vests in one installment on February 14, 2022.
(11)	Grant of option to buy 10,148 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2019.
(12)	Grant of option to buy 560 shares of Issuer common stock that vests in one installment on February 14, 2023.
(13)	The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Turner Kathy V C/O IDEXX LABORATORIES, INC. ONE IDEXX DRIVE WESTBROOK, ME 04092			Corporate Vice President

Signatures
/s/ Kathy V. Turner		5/21/2018
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.